Members

Tango Therapeutics

Member Type: Emerging Biotech/Pharmaceutical Companies

Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies and extend the benefit of available immuno-oncology agents.

https://www.tangotx.com

Join Today

PMC members shape and advance the future of personalized medicine.
Join Today




Download a Member List